Details for Patent: 9,387,266

✉ Email this page to a colleague

Which drugs does patent 9,387,266 protect, and when does it expire?

Patent 9,387,266 protects AXUMIN and is included in one NDA.

This patent has twenty-nine patent family members in sixteen countries.

Summary for Patent: 9,387,266

Title:	Precursor compound of radioactive halogen-labeled organic compound
Abstract:	It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [.sup.18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: ##STR00001## wherein n is an integer of 0 or of 1 to 4; R.sup.1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by --OR.sup.2; R.sup.2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R.sup.3 is a protective group.
Inventor(s):	Ito; Osamu (Chiba, JP), Hayashi; Akio (Chiba, JP), Kurosaki; Fumie (Chiba, JP), Toyama; Masahito (Chiba, JP), Shinmura; Toshiyuki (Chiba, JP), Harano; Arinori (Chiba, JP)
Assignee:	NIHON MEDI-PHYSICS CO., LTD. (Tokyo, JP)
Application Number:	14/814,185
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,387,266

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Blue Earth	AXUMIN	fluciclovine f-18	SOLUTION;INTRAVENOUS	208054-001	May 27, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,387,266

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2005-343653	Nov 29, 2005

International Family Members for US Patent 9,387,266

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006319987	⤷ Sign Up
Brazil	PI0619213	⤷ Sign Up
Canada	2629227	⤷ Sign Up
China	101316812	⤷ Sign Up
European Patent Office	1978015	⤷ Sign Up
European Patent Office	3354639	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.